-+ 0.00%
-+ 0.00%
-+ 0.00%

BIOGEN - EXPECTS Q1 2026 $34 MLN BOUGHT IN-PROCESS R&D, UPFRONT AND MILESTONE EXPENSE - SEC FILING

Reuters·04/06/2026 10:32:16

Please log in to view news